Stryker Corporation (NYSE:SYK) Receives Consensus Rating of "Moderate Buy" from Brokerages
Stryker Corporation (NYSE:SYK) has received a consensus rating of 'Moderate Buy' from eighteen brokerages. Six analysts rated the stock as hold, while twelve gave a buy recommendation. The average 1-year target price is $431.83. Recent insider trading saw significant share sales by Director Ronda E. Stryker and CAO William E. Berry, Jr. Institutional investors own 77.09% of the company's stock. Stryker's recent quarterly earnings beat estimates with $3.19 EPS and $6.06 billion in revenue, showing a 10.2% increase from the previous year.
Shares of Stryker Corporation (NYSE:SYK - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eighteen brokerages that are presently covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $431.8333.
- Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?
A number of brokerages have weighed in on SYK. Citigroup cut their target price on shares of Stryker from $455.00 to $420.00 and set a "buy" rating for the company in a research report on Thursday. Rothschild Redb raised shares of Stryker to a "hold" rating in a report on Thursday, September 18th. Needham & Company LLC reaffirmed a "buy" rating and issued a $448.00 price target on shares of Stryker in a report on Friday, November 14th. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Finally, Wells Fargo & Company increased their price objective on Stryker from $452.00 to $456.00 and gave the stock an "overweight" rating in a report on Friday, November 14th.
View Our Latest Research Report on SYK
Insider Buying and Selling
- Beware the Death Cross: 3 Stocks Triggering This Spooky Signal
In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the business's stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares of the company's stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 522,118 shares of company stock valued at $185,381,932. Company insiders own 5.90% of the company's stock.
Institutional Trading of Stryker
A number of large investors have recently modified their holdings of SYK. Severin Investments LLC raised its stake in Stryker by 24.1% in the third quarter. Severin Investments LLC now owns 1,499 shares of the medical technology company's stock valued at $554,000 after purchasing an additional 291 shares in the last quarter. Swiss Life Asset Management Ltd lifted its holdings in shares of Stryker by 7.0% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 37,984 shares of the medical technology company's stock worth $14,042,000 after acquiring an additional 2,486 shares during the last quarter. Stillwater Wealth Management Group bought a new stake in shares of Stryker during the 3rd quarter worth $2,960,000. Investment Research Partners LLC purchased a new position in Stryker in the third quarter worth $423,000. Finally, Cambria Investment Management L.P. bought a new position in Stryker in the third quarter valued at $223,000. Institutional investors own 77.09% of the company's stock.
Stryker Price Performance
- If You Could Only Hold 3 Investments for Life, Consider These
Shares of NYSE SYK opened at $353.99 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. The stock has a fifty day simple moving average of $366.81 and a two-hundred day simple moving average of $378.46. Stryker has a 1-year low of $329.16 and a 1-year high of $406.19. The firm has a market cap of $135.37 billion, a price-to-earnings ratio of 46.52, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating analysts' consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $6.06 billion for the quarter, compared to analysts' expectations of $6.04 billion. During the same quarter in the prior year, the firm earned $2.87 EPS. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts anticipate that Stryker will post 13.47 earnings per share for the current year.
Stryker Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. This is an increase from Stryker's previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. Stryker's dividend payout ratio (DPR) is 44.15%.
About Stryker
(Get Free Report)Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Recommended Stories
- Five stocks we like better than Stryker
- Investing In Automotive Stocks
- Disney's $1 Billion Deal Brings Its Magic to OpenAI
- How is Compound Interest Calculated?
- Why Amazon Could Be a $300 Stock Within Weeks
- High Flyers: 3 Natural Gas Stocks for March 2022
- Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Stryker Right Now?
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
